MR Elastography of the Pancreas: Bowel Preparation and Repeatability Assessment in Pancreatic Cancer Patients and

Nienke P M Wassenaar1,2, Anne-Sophie van Schelt1,2, Eric M Schrauben1

  • 1Department of Radiology and Nuclear Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.

Abstract

Insights

Bowel preparation regimens do not significantly impact MR elastography (MRE) quality for pancreatic cancer. MRE can differentiate between tumor and healthy tissues, supporting its clinical use.

Area of Science:

  • Medical imaging
  • Biophysics
  • Oncology

Background:

  • Pancreatic ductal adenocarcinoma (PDAC) involves measuring stromal viscoelasticity using MR elastography (MRE).
  • Bowel preparation regimens may influence MRE quality, necessitating research into their repeatability for clinical application.

Purpose of the Study:

  • To evaluate the impact of four distinct bowel preparation regimens on MRE quality.
  • To assess the repeatability of MRE and its ability to differentiate between PDAC patients and healthy controls.

Main Methods:

  • Prospective study involving 25 controls and 15 PDAC patients.
  • Four bowel preparation regimens were tested: fasting, scopolaminebutyl, water intake, and a combination.
  • MRE signal-to-noise ratio (SNR), shear wave speed (SWS), and phase angle (ϕ) were assessed, along with repeatability and inter/intra-observer variability.

Main Results:

  • Bowel preparation regimens did not significantly affect MRE-SNR, leading to the adoption of the simplest regimen (fasting only).
  • Repeatability coefficients of variation (CoVs) for tumor SWS were 12.8% (intrasession) and 21.7% (intersession).
  • Significant differences in SWS and ϕ were observed between tumor, nontumor, and healthy pancreatic tissues, except for ϕ between healthy and nontumor tissue.

Conclusions:

  • The evaluated bowel preparation regimens do not appear to compromise MRE quality.
  • MRE demonstrates potential in distinguishing between healthy pancreatic tissue, tumor tissue, and nontumorous tissue in PDAC patients.